Published in Lung Cancer on May 11, 2006
VEGF targets the tumour cell. Nat Rev Cancer (2013) 2.71
MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer (2010) 1.48
SCF(β-TRCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. J Exp Med (2012) 1.18
Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. Br J Cancer (2013) 1.08
Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. J Thorac Oncol (2013) 1.05
Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res (2011) 1.05
The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia (2013) 1.02
Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors. Am J Surg Pathol (2012) 0.94
Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives. Onco Targets Ther (2014) 0.91
Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. Cancer (2011) 0.90
Expression profiling and identification of potential molecular targets for therapy in pulmonary large-cell neuroendocrine carcinoma. Exp Ther Med (2011) 0.88
Association between vascular endothelial growth factor gene polymorphisms and bladder cancer risk. Mol Clin Oncol (2014) 0.87
VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy. Clin Cancer Res (2014) 0.87
VEGF spliced variants: possible role of anti-angiogenesis therapy. J Nucleic Acids (2011) 0.86
Tumor cell response to bevacizumab single agent therapy in vitro. Cancer Cell Int (2013) 0.82
Personalizing lung cancer prevention through a reverse migration strategy. Top Curr Chem (2013) 0.82
The role of anti-angiogenesis in non-small-cell lung cancer: an update. Curr Oncol Rep (2015) 0.79
Clinical development of nintedanib for advanced non-small-cell lung cancer. Ther Clin Risk Manag (2015) 0.78
Personalized therapy for non-small cell lung cancer: which drug for which patient? Semin Thorac Cardiovasc Surg (2011) 0.78
Gemcitabine and paclitaxel suppress the production of vascular endothelial growth factor induced by deferoxamine in human non-small cell lung cancer A549 cells. Exp Ther Med (2010) 0.77
[Bevacizumab in the first-line therapy of advanced NSCLC]. Wien Med Wochenschr (2007) 0.77
Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer. Oncol Lett (2015) 0.77
Vascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer. Int J Oncol (2015) 0.76
Fibroblast Growth Factor Receptor 1 (FGFR1), Partly Related to Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) and Microvessel Density, is an Independent Prognostic Factor for Non-Small Cell Lung Cancer. Med Sci Monit (2017) 0.75
Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer. BMC Med Genomics (2014) 0.75
Expression of VEGFR2 and NRP-1 in non-small cell lung cancer and their clinical significance. Chin J Cancer Res (2014) 0.75
Identification of mutant genes with high-frequency, high-risk, and high-expression in lung adenocarcinoma. Thorac Cancer (2014) 0.75
Diffuse alveolar haemorrhage may be associated with intravitreal injection of bevacizumab in a patient with systemic risk factors. BMJ Case Rep (2011) 0.75
The use of pharmacogenomics for selection of therapy in non-small-cell lung cancer. Clin Med Insights Oncol (2014) 0.75
Plasma vascular endothelial growth factor 165 in advanced non-small cell lung cancer. Oncol Lett (2014) 0.75
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. Clin Cancer Res (2015) 0.75
Prognostic significance of combining VEGFA, FLT1 and KDR mRNA expression in lung cancer. Oncol Lett (2015) 0.75
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 46.35
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med (2004) 6.36
Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol (2010) 5.99
Radical sublobar resection for small-sized non-small cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg (2006) 3.93
CT-guided needle biopsy of lung lesions: a survey of severe complication based on 9783 biopsies in Japan. Eur J Radiol (2006) 3.39
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol (2010) 3.30
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol (2008) 3.27
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med (2008) 3.00
Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol (2005) 2.87
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res (2005) 2.81
Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol (2010) 2.55
International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol (2012) 2.44
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both. J Clin Oncol (2013) 2.37
Effects of a programme of interventions on regional comprehensive palliative care for patients with cancer: a mixed-methods study. Lancet Oncol (2013) 2.34
Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res (2011) 2.23
Screening for lung cancer with low-dose helical computed tomography: anti-lung cancer association project. J Clin Oncol (2002) 2.18
Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci (2008) 2.17
SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A (2003) 2.12
A Japanese Lung Cancer Registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol (2008) 2.01
Impact of energy devices during liver parenchymal transection: a multicenter randomized controlled trial. World J Surg (2015) 1.98
Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene (2004) 1.93
Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol (2006) 1.88
Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol (2012) 1.86
Perceptions and attitudes of clinical oncologists on complementary and alternative medicine: a nationwide survey in Japan. Cancer (2003) 1.82
Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma. J Thorac Oncol (2011) 1.81
Focal ground-glass opacity detected by low-dose helical CT. Chest (2002) 1.79
Frequency of and variables associated with the EGFR mutation and its subtypes. Int J Cancer (2010) 1.79
An antagonist of dishevelled protein-protein interaction suppresses beta-catenin-dependent tumor cell growth. Cancer Res (2007) 1.73
Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One (2011) 1.73
Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci (2010) 1.72
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol (2011) 1.71
Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. Lung Cancer (2005) 1.71
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer (2012) 1.67
An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant melanoma cells and inhibits tumor growth. Cancer Res (2004) 1.64
Sublobar resection provides an equivalent survival after lobectomy in elderly patients with early lung cancer. Ann Thorac Surg (2010) 1.62
Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol (2012) 1.62
Advances in esophageal cancer surgery in Japan: an analysis of 1000 consecutive patients treated at a single institute. Surgery (2008) 1.57
Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. Ann Surg (2013) 1.56
Virus-associated hemophagocytic syndrome in an international traveler as a differential diagnosis of SARS. Intern Med (2005) 1.54
A monoclonal antibody against Wnt-1 induces apoptosis in human cancer cells. Neoplasia (2004) 1.54
Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. J Thorac Oncol (2011) 1.53
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol (2008) 1.53
Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III non-small cell lung cancer. Ann Thorac Surg (2013) 1.44
Intramuscular transplantation of G-CSF-mobilized CD34(+) cells in patients with critical limb ischemia: a phase I/IIa, multicenter, single-blinded, dose-escalation clinical trial. Stem Cells (2009) 1.43
Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol (2004) 1.42
Reassessment of the utility of frozen sections in endometrial cancer surgery using tumor diameter as an additional factor. Am J Obstet Gynecol (2011) 1.41
Intrathoracic chemo-thermotherapy with radiofrequency waves after extrapleural pneumonectomy for malignant pleural mesothelioma. Interact Cardiovasc Thorac Surg (2011) 1.39
Pulmonary resection in patients aged 80 years or over with clinical stage I non-small cell lung cancer: prognostic factors for overall survival and risk factors for postoperative complications. J Thorac Oncol (2009) 1.38
Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Res Treat (2010) 1.33
Treatment outcome of resected and nonresected primary adenoid cystic carcinoma of the lung. Ann Thorac Cardiovasc Surg (2002) 1.32
Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res (2008) 1.32
Possibility of multivariate function composed of plasma amino acid profiles as a novel screening index for non-small cell lung cancer: a case control study. BMC Cancer (2010) 1.31
Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg (2005) 1.30
Natural history of pure ground-glass opacity after long-term follow-up of more than 2 years. Ann Thorac Surg (2002) 1.30
Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer (2008) 1.27
Long-term results of surgical resection for pulmonary metastasis from renal cell carcinoma: a 25-year single-institution experience. Eur J Cardiothorac Surg (2010) 1.25
Clinical significance of the 21-gene signature (Oncotype DX) in hormone receptor-positive early stage primary breast cancer in the Japanese population. Cancer (2010) 1.23
The significance of surgical resection for pulmonary metastasis from hepatocellular carcinoma. Am J Surg (2006) 1.22
Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells. Cancer Res (2004) 1.22
Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma. Clin Cancer Res (2010) 1.22
Risk factors associated with surgical site infection in upper and lower gastrointestinal surgery. Surg Today (2008) 1.22
Prospective study of thoracoscopic limited resection for ground-glass opacity selected by computed tomography. Ann Thorac Surg (2003) 1.20
Quantitative identification of mutant alleles derived from lung cancer in plasma cell-free DNA via anomaly detection using deep sequencing data. PLoS One (2013) 1.19
Visceral pleura invasion impact on non-small cell lung cancer patient survival: its implications for the forthcoming TNM staging based on a large-scale nation-wide database. J Thorac Oncol (2009) 1.19
A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg (2003) 1.18
Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. J Clin Oncol (2008) 1.16
Progression of focal pure ground-glass opacity detected by low-dose helical computed tomography screening for lung cancer. J Comput Assist Tomogr (2004) 1.13
Japanese Lung Cancer Registry Study: first prospective enrollment of a large number of surgical and nonsurgical cases in 2002. J Thorac Oncol (2010) 1.13
Triplet chemotherapy for malignant pericardial mesothelioma: a case report. Jpn J Clin Oncol (2006) 1.13
Fractal analysis of small peripheral pulmonary nodules in thin-section CT: evaluation of the lung-nodule interfaces. J Comput Assist Tomogr (2002) 1.11
Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. Clin Cancer Res (2002) 1.10
Aberrant expression of connexin 26 is associated with lung metastasis of colorectal cancer. Clin Cancer Res (2008) 1.08
Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma. Breast Cancer Res Treat (2006) 1.08
Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. Mol Cancer Ther (2002) 1.07
Treatment strategy for patients with small peripheral lung lesion(s): intermediate-term results of prospective study. Eur J Cardiothorac Surg (2008) 1.07
Cloning and characterization of a functional promoter of the human SOCS-3 gene. Biochem Biophys Res Commun (2003) 1.07
Malignant schwannoma of the upper mediastinum originating from the vagus nerve. World J Surg Oncol (2005) 1.06
Impact of positive pleural lavage cytology on survival in patients having lung resection for non-small-cell lung cancer: An international individual patient data meta-analysis. J Thorac Cardiovasc Surg (2009) 1.06
Efficacy of Wnt-1 monoclonal antibody in sarcoma cells. BMC Cancer (2005) 1.05
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Res Treat (2009) 1.05
A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304). Lung Cancer (2004) 1.04
Intrathoracic omental herniation through the esophageal hiatus in a young patient. Jpn J Thorac Cardiovasc Surg (2005) 1.03
Providing palliative care for cancer patients: the views and exposure of community general practitioners and district nurses in Japan. J Pain Symptom Manage (2011) 1.03
Outcome of surgical resection of pulmonary metastasis from urinary tract transitional cell carcinoma. Interact Cardiovasc Thorac Surg (2010) 1.03
Surgical results of lung cancer with sarcoid reaction in regional lymph nodes. Jpn J Clin Oncol (2007) 1.03
Preferred place of care and place of death of the general public and cancer patients in Japan. Support Care Cancer (2012) 1.03
Outcome of surgical resection for recurrent pulmonary metastasis from colorectal carcinoma. Am J Surg (2011) 1.02
Occult mediastinal lymph node metastasis in NSCLC patients diagnosed as clinical N0-1 by preoperative integrated FDG-PET/CT and CT: Risk factors, pattern, and histopathological study. Lung Cancer (2010) 1.02
Surgical outcome of stage IIIA- cN2/pN2 non-small-cell lung cancer patients in Japanese lung cancer registry study in 2004. J Thorac Oncol (2012) 1.02